Alnylam Pharmaceuticals, Inc. (ALNY) Stock Trending Up After Price Target Increase at Chardan Capital

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares rose in early trading today on lighter trade volume than normal after a number of analysts weighed in on the investing value of the stock, increasing the price target of stock.

Meanwhile, U.S. stocks edged lower Monday, with major indexes retreating from record levels.

The Dow Jones Industrial Average DJIA, -0.31% fell 48 points, or 0.2%, to 19,916, while the S&P 500 index SPX, -0.29% lost 5 points to 2,272, a drop of 0.2%. The Nasdaq Composite Index COMP, -0.03% rose 4 points to 5,529, a gain of about 0.1%.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target boosted by equities researchers at Chardan Capital from $0.00 to $97.00. The company currently has a rating of on the shares. The one-year price target of $61.36 is above the opening price of $42.89, causing a number of other analysts to comment on the company in recent days. Looking back over the last 52 weeks, Alnylam Pharmaceuticals, Inc. stock has a high of $88.11.

Yesterday Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares last traded at $43.35, which is a jump of $1.12 from the previous closing price. Opening at $42.89, they varied from $42.50 and $43.50 throughout the day.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) now has a market cap of 3.72B.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Average Daily Trading Volume

151,107 shares crossed the trading desk yesterday, 63 percent below normal, out of a total float 70,877,000. lower than normal. Look for trading volume to pick up in the coming days as investors often use upticks in trading volume to identify heavy volume accumulation or distribution by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to watch for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have teams of analysts researching thousands of stocks, so it is good corroboration to see them taking a postion in a stock you’re considering.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.

With that in mind, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) now has a 50-day MA of $42.52 and 200-day MA of $55.82. It has traded in a 52-week range between $31.38 – 88.11 and today’s last price is 50.80%% lower than the 52 week high of $88.11.

Earnings growth is a crucial factor to research when investing in stocks and investors identify companies that have increased their earnings at least 25% or more for the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *